Inhibition of CD200R1 expression by C/EBP beta in reactive microglial cells

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Dentesano, Guido ^a   Straccia, Marco ^a,b   Ejarque Ortiz, Aroa ^a   Tusell, Josep M ^a   Serratosa, Joan ^a   Saura, Josep ^b   Solà, Carme ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

C EBP ; CD200R1; In vitro; Neuroinflammation; Neuron microglia communication; Reactive microglia

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; CD200 ANTIGEN; CD200 RECEPTOR; CD200R1 PROTEIN; HISTONE DEACETYLASE 1; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD200R1 GENE; CONTROLLED STUDY; EMBRYO; FEMALE; GENE OVEREXPRESSION; MICROGLIA; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATORY MECHANISM; WILD TYPE;

EID: 84863520025     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-165     Document Type: Article

References (63)

1. Hanish UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007, 10:1387-1394. 10.1038/nn1997, 17965659.
2. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009, 27:119-145. 10.1146/annurev.immunol.021908.132528, 19302036.
3. Gao H-M, Hong J-S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008, 29:357-365. 10.1016/j.it.2008.05.002, 18599350.
4. Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system parenchyma. Nature 2010, 468:253-262. 10.1038/nature09615, 21068834.
5. Boudakov I, Liu J, Fan N, Gulay P, Wong K, Gorczynski RM. Mice lacking CD200R1 show absence of suppression of lipopolysaccharide-induced tumor necrosis factor-α and mixed leukocyte culture responses by CD200. Transplantation 2007, 84:251-257. 10.1097/01.tp.0000269795.04592.cc, 17667818.
6. Broderick C, Hoek RM, Forrester JV, Liversidge J, Sedgwick JD, Dick AD. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Amm J Pathol 2002, 161:1669-1677.
7. Copland DA, Calder CJ, Raveney BJ, Nicholson LB, Phillips J, Cherwinski H, Jenmalm M, Sedgwick JD, Dick AD. Monoclonal antibody-mediated CD200 receptor signalling supresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am J Pathol 2007, 171:396-398. 10.2353/ajpath.2007.070474, 1934540, 17600125.
8. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, Barclay AN, Sedgwick JD. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000, 290:1768-1771.
9. Lyons A, Downer EJ, Crotty S, Nolan YM, Mills KH, Lynch MA. CD200 ligand-receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. J Neurosci 2007, 27:8309-8313. 10.1523/JNEUROSCI.1781-07.2007, 17670977.
10. Lyons A, McQuillan A, Deighan BF, O'Reilly J-A, Downer EJ, Murphy AC, Watson M, Piazza A, O'Connell F, Griffin R, Mills KHG, Lynch MA. Decreased neuronal CD200 expression in IL-4-deficient mice results in increased neuroinflammation in response to lipopolysaccharide. Brain Behav Immun 2009, 23:1020-1027. 10.1016/j.bbi.2009.05.060, 19501645.
11. Koning N, Bö L, Hoek RM, Huitinga I. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann Neurol 2007, 62:504-514. 10.1002/ana.21220, 17879969.
12. Koning N, Swaab DF, Hoek RM, Huitinga I. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions. J Neuropathol Exp Neurol 2009, 68:159-167. 10.1097/NEN.0b013e3181964113, 19151626.
13. Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue L-F. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp Neurol 2009, 215:5-19. 10.1016/j.expneurol.2008.09.003, 2765462, 18938162.
14. Rosenblum MD, Olasz E, Woodliff JE, Johnson BD, Konkol MC, Gerber KA, Orentas RJ, Sandford G, Truitt RL. CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance. Blood 2008, 103:2691-2698.
15. Chen Z, Marsden PA, Gorczynski RM. Cloning and characterization of the human CD200 promoter region. Mol Immunol 2006, 43:579-587. 10.1016/j.molimm.2005.04.014, 15955564.
16. Chen Z, Marsden PA, Gorczynski RM. Role of a distal enhancer in the transcriptional responsiveness of the human CD200 gene to interferon-γ and tumor necrosis factor-α. Mol Immunol 2009, 46:1951-1963. 10.1016/j.molimm.2009.03.015, 19386363.
17. Cortes-Canteli M, Luna-Medina R, Sanz-Sancristobal M, Alvarez-Barrientos A, Santos A, Perez-Castillo A. CCAAT/enhancer binding protein beta deficiency provides cerebral protection following excitotoxic injury. J Cell Sci 2008, 121:1224-1234. 10.1242/jcs.025031, 18388310.
18. Straccia M, Gresa-Arribas N, Dentesano G, Ejarque-Ortiz A, Tusell JM, Serratosa J, Solà C, Saura J. Pro-inflammatory gene expression and neurotoxic effects of activated microglia are attenuated by absence of CCAAT/enhancer binding protein beta. J Neuroinflam 2011, 8:156-170.
19. Screpanti I, Romani L, Musiani P, Modesti A, Fattori E, Lazzaro D, Sellitto C, Scarpa S, Bellavia D, Lattanzio G, et al. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J 1995, 14:1932-1941. 398292, 7744000.
20. Gresa-Arribas N, Serratosa J, Saura J, Solà C. Inhibition of CCAAT/enhancer binding protein δ expression by chrysin in microglial cells results in anti-inflammatory and neuroprotective effects. J Neurochem 2010, 115:526-536. 10.1111/j.1471-4159.2010.06952.x, 20722966.
21. Saura J, Tusell JM, Serratosa J. High-yield isolation of murine microglia by mild trypsinization. Glia 2003, 44:183-189. 10.1002/glia.10274, 14603460.
22. Saura J, Angulo E, Ejarque A, Casado V, Tusell JM, Moratalla R, Chen J-F, Schwarzschild MA, Lluis C, Franco R, Serratosa J. Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem 2005, 95:919-929. 10.1111/j.1471-4159.2005.03395.x, 16092928.
23. Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F. Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol 1990, 27:229-237. 10.1016/0165-5728(90)90073-V, 2110186.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
25. Wright GJ, Puklavec MJ, Willis AC, Hoek RM, Sedgwick JD, Brown MH, Barclay AM. Lymphoid/neuronal cell surface glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 2000, 13:233-242. 10.1016/S1074-7613(00)00023-6, 10981966.
26. Meuth SG, Simon OJ, Grimm A, Melzer N, Herrmann AM, Spitzer P, Landgraf P, Wiendl H. CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing. J Neuroimmunol 2008, 194:62-69. 10.1016/j.jneuroim.2007.11.013, 18164423.
27. Liu Y, Bando Y, Vargas-Lowy D, Elyaman W, Khoury SJ, Huang T, Reif K, Chitnis T. CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J Neurosci 2010, 30:2025-2038. 10.1523/JNEUROSCI.4272-09.2010, 2837938, 20147531.
28. Chitnis T, Imitola J, Wang Y, Elyaman W, Chawla P, Sharuk M, Raddassi K, Bronson RT, Koury SJ. Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. Am J Pathol 2007, 170:1695-1712. 10.2353/ajpath.2007.060677, 1854964, 17456775.
29. Zhang S, Cherwinski H, Sedgwick JD, Phillips JH. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol 2004, 173:6786-6793.
30. Mihrshahi R, Barclay AN, Brown MH. Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells. J Immunol 2009, 183:4879-4886. 10.4049/jimmunol.0901531, 2788151, 19786546.
31. Ejarque-Ortiz A, Medina MG, Tusell JM, Pérez-González AP, Serratosa J, Saura J. Upregulation of CCAAT/enhancer binding protein β in activated astrocytes and microglia. Glia 2007, 55:178-188. 10.1002/glia.20446, 17078024.
32. Valente T, Mancera P, Tusell JM, Serratosa J, Saura J. C/EBPβ expression in activated microglia in amyotrophic lateral sclerosis. Neurobiol Aging in press.
33. Pérez-Capote K, Saura J, Serratosa J, Solà C. Expression of C/EBPalpha and C/EBPbeta in glial cells in vitro after inducing glial activation by different stimuli. Neuroscience Lett 2006, 410:25-30.
34. Lowenstein CJ, Alley EW, Raval P, Snowman AM, Snyder SH, Russell SW, Murphy WJ. Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc Natl Acad Sci U S A 1993, 90:9730-9734. 10.1073/pnas.90.20.9730, 47644, 7692452.
35. Wadleigh DJ, Reddy ST, Kopp E, Ghosh S, Herschman HR. Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages. J Biol Chem 2000, 275:6259-6266. 10.1074/jbc.275.9.6259, 10692422.
36. Caivano M, Gorgoni B, Cohen P, Poli V. The induction of cyclooxygenase-2 mRNA in macrophages is biphasic and requires both CCAAT enhancer-binding protein beta (C/EBP beta) and C/EBP delta transcription factors. J Biol Chem 2001, 276:48693-48701. 10.1074/jbc.M108282200, 11668179.
37. Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, Kishimoto T, Akira S. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A 1993, 90:10193-10197. 10.1073/pnas.90.21.10193, 47740, 8234276.
38. Liu H, Sidiropoulos P, Song G, Pagliari LJ, Birrer MJ, Stein B, Anrather J, Pope RM. TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta. J Immunol 2000, 164:4277-4285.
39. Gorgoni B, Maritano D, Marthyn P, Righi M, Poli V. C/EBP beta gene inactivation causes both impaired and enhanced gene expression and inverse regulation of IL-12 p40 and p35 mRNAs in macrophages. J Immunol 2002, 168:4055-4062.
40. Chen J, Ivashkiv LB. IFN-γ abrogates endotoxin tolerance by facilitating toll-like receptor-induced chromatin remodeling. Proc Natl Acad Sci U S A 2010, 107:19438-19443. 10.1073/pnas.1007816107, 2984206, 20974955.
41. Yan C, Cao J, Wu M, Zhang W, Jiang T, Yoshimura A, Gao H. Suppressor of cytokine signaling 3 inhibits LPS-induced IL-6 expression in osteoblasts by suppressing CCAAT/enhancer-binding protein beta activity. J Biol Chem 2010, 285:37227-37239. 10.1074/jbc.M110.132084, 2988329, 20876575.
42. Kapadia R, Tureyen K, Bowen KK, Kalluri H, Johnson PF, Vemuganti R. Decreased brain damage and curtailed inflammation in transcription factor CCAAT/enhancer binding protein beta knockout mice following transient focal cerebral ischemia. J Neurochem 2006, 98:1718-1731. 10.1111/j.1471-4159.2006.04056.x, 16899075.
43. Liu YW, Tseng HP, Chen LC, Chen BK, Chang WC. Functional cooperation of simian virus 40 promoter factor 1 and CCAAT/enhancer-binding protein beta and delta in lipopolysaccharide-induced gene activation of IL-10 in mouse macrophages. J Immunol 2003, 171:821-828.
44. Liu YW, Chen CC, Tseng HP, Chang WC. Lipopolysaccharide-induced transcriptional activation of interleukin-10 is mediated by MAPK- and NF-kappaB-induced CCAAT/enhancer-binding protein delta in mouse macrophages. Cell Signal 2006, 18:1492-1500. 10.1016/j.cellsig.2005.12.001, 16413748.
45. Brenner S, Prösch S, Schenke-Layland K, Riese U, Gausmann U, Platzer C. cAMP-induced interleukin-10 promoter activation depends on CCAAT/enhancer-binding protein expression and monocytic differentiation. J Biol Chem 2003, 278:5597-5604. 10.1074/jbc.M207448200, 12493739.
46. Csóka B, Németh ZH, Virág L, Gergely P, Leibovich SJ, Pacher P, Sun CX, Blackburn MR, Vizi ES, Deitch EA, Haskó G. A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood 2007, 110:2685-2695. 10.1182/blood-2007-01-065870, 1988939, 17525287.
47. Eaton EM, Sealy L. Modification of CCAAT/enhancer-binding protein-beta by the small ubiquitin-like modifier (SUMO) family members, SUMO-2 and SUMO-3. J Biol Chem 2003, 278:33416-33421. 10.1074/jbc.M305680200, 12810706.
48. Wang W-L, Lee Y-C, Yang W-M, Chang W-M, Chang W-C, Wang J-M. Sumoylation of LAP1 is involved in the HDAC4-mediated repression of COX-2 transcription. Nucleic Acid Res 2008, 36:6066-6079. 10.1093/nar/gkn607, 2577330, 18820298.
49. Ghosh AK, Bhattacharyya S, Mori Y, Varga J. Inhibition of collagen gene expression by interferon-gamma: novel role of the CCAAT/enhancer binding protein beta (C/EBPbeta). J Cell Physiol 2006, 207:251-260. 10.1002/jcp.20559, 16331681.
50. Dong L-Y, Sun G, Jiang L, Shao L, Hu Y, Jiang Y, Wang Y, An W. Epidermal growth factor down-regulates the expression of human hepatic stimulator substance via CCAAT/enhancer-binding protein β in HepG2 cells. Biochem J 2010, 431:277-287. 10.1042/BJ20100671, 20690902.
51. Pless O, Kowenz-Leutz E, Knoblich M, Lausen J, Beyermann M, Walsch MJ, Leutz A. G9a-mediated lysine methylation alters the function of CCAAT/enhancer-binding protein-beta. J Biol Chem 2008, 283:26357-26363. 10.1074/jbc.M802132200, 3258912, 18647749.
52. Ceseña TI, Cui TX, Subramanian L, Fulton CT, Iñiguez-Lluhí JA, Kwok RPS, Schwartz J. Acetylation and deacetylation regulate CCAAT/enhancer binding protein β at K39 in mediating gene transcription. Mol Cell Endocrinol 2008, 289:94-101. 10.1016/j.mce.2008.03.009, 18486321.
53. Xu M, Nie L, Kim SH, Sun XH. STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta. EMBO J 2003, 22:893-904. 10.1093/emboj/cdg094, 145454, 12574125.
54. Li X, Molina H, Huang H, Zhang YY, Liu M, Qian SW, Slawson C, Dias WB, Pandey A, Hart GW, Lane MD, Tang QQ. O-linked N-acetylflucosamine modification on CCAAT enhancer-binding protein beta: role during adipocyte differentiation. J Biol Chem 2009, 284:19248-19254. 10.1074/jbc.M109.005678, 2740549, 19478079.
55. Di-Poï N, Desvergne B, Michalik L, Wahli W. Transcriptional repression of peroxisome proliferator-activated receptor β/δ in murine keratinocytes by CCAAT/enhancer-binding proteins. J Biol Chem 2005, 280:38700-38710. 10.1074/jbc.M507782200, 16166081.
56. Wiper-Bergeron N, Wu D, Pope L, Schild-Poulter C, Haché RJ. Stimulation of preadipocyte differentiation by steroid through targeting of an HDAC1 complex. EMBO J 2003, 22:2135-2145. 10.1093/emboj/cdg218, 156090, 12727880.
57. Zuo Y, Qiang L, Farmer SR. Activation of CCAAT/enhancer-binding protein (C/EBP) expression by C/EBPβ during adipogenesis requires a peroxisome proliferators-activated receptor-γ-associated repression of HDAC1 at the C/ebpα gene promoter. J Biol Chem 2006, 281:7960-7967. 10.1074/jbc.M510682200, 16431920.
58. Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007, 76:75-100. 10.1146/annurev.biochem.76.052705.162114, 17362198.
59. Faraco G, Pittelli M, Cavone L, Fossati S, Porcu M, Mascagni P, Fossati G, Moroni F, Chiarugi A. Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Dis 2009, 36:269-279. 10.1016/j.nbd.2009.07.019, 19635561.
60. Bode KA, Schroder K, Hume DA, Ravasi T, Heeg K, Sweet MJ, Dalpke AH. Histone deacetylase inhibitors decrease toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 2007, 122:596-606. 10.1111/j.1365-2567.2007.02678.x, 2266046, 17635610.
61. Choi Y, Park SK, Kim HM, Kang JS, Yoon YD, Han SB, Han JW, Yang JS, Han G. Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in in vivo endotoxemia model. Exp Mol Med 2008, 40:574-581. 10.3858/emm.2008.40.5.574, 2679350, 18985016.
62. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, Reznikov LL, Siegnund B, Fantuzzi G, Dinarello CA, Mascagni P. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005, 11:1-15. 1449516, 16557334.
63. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chiang DM. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007, 321:892-901. 10.1124/jpet.107.120188, 17371805.